OBJECTIVE: To develop an objective tool for assessing disease activity in patients with Langerhans cell histiocytosis (LCH). METHOD: Scoring system was developed and applied to a database containing information on 612 patients. RESULTS: At diagnosis, the score distribution was highly asymmetrical: the score was between 0 and 2 in 74% of cases, 3-6 in 16%, 7-10 in 3%, and more than 10 in 6%. The 5-year mortality rates were 1, 4.4, and 43.4%, respectively, among patients with initial scores of 0-2, 3-6, and >6. Stability or an increase of the score at 6 weeks was highly predictive of death among patients with initial scores above 6, while score stability had no significant impact on vital outcome among patients with low or moderate scores at diagnosis. CONCLUSIONS: This LCH disease activity score provides an objective tool for assessing disease severity, both at diagnosis and during follow-up and treatment. 2004 Wiley-Liss, Inc.
OBJECTIVE: To develop an objective tool for assessing disease activity in patients with Langerhans cell histiocytosis (LCH). METHOD: Scoring system was developed and applied to a database containing information on 612 patients. RESULTS: At diagnosis, the score distribution was highly asymmetrical: the score was between 0 and 2 in 74% of cases, 3-6 in 16%, 7-10 in 3%, and more than 10 in 6%. The 5-year mortality rates were 1, 4.4, and 43.4%, respectively, among patients with initial scores of 0-2, 3-6, and >6. Stability or an increase of the score at 6 weeks was highly predictive of death among patients with initial scores above 6, while score stability had no significant impact on vital outcome among patients with low or moderate scores at diagnosis. CONCLUSIONS: This LCH disease activity score provides an objective tool for assessing disease severity, both at diagnosis and during follow-up and treatment. 2004 Wiley-Liss, Inc.
Authors: Jean-François Emile; Oussama Abla; Sylvie Fraitag; Annacarin Horne; Julien Haroche; Jean Donadieu; Luis Requena-Caballero; Michael B Jordan; Omar Abdel-Wahab; Carl E Allen; Frédéric Charlotte; Eli L Diamond; R Maarten Egeler; Alain Fischer; Juana Gil Herrera; Jan-Inge Henter; Filip Janku; Miriam Merad; Jennifer Picarsic; Carlos Rodriguez-Galindo; Barret J Rollins; Abdellatif Tazi; Robert Vassallo; Lawrence M Weiss Journal: Blood Date: 2016-03-10 Impact factor: 22.113
Authors: Won-Ik Choi; You Cheol Jeong; Sun Young Kim; So Dam Kim; John Paul Pribis; Hee-Jin Kim; Kyung-Nam Koh; Ho-Joon Im; Young-Ho Lee; Jong-Jin Seo Journal: Korean J Hematol Date: 2011-09-30
Authors: Riccardo Haupt; Milen Minkov; Itziar Astigarraga; Eva Schäfer; Vasanta Nanduri; Rima Jubran; R Maarten Egeler; Gritta Janka; Dragan Micic; Carlos Rodriguez-Galindo; Stefaan Van Gool; Johannes Visser; Sheila Weitzman; Jean Donadieu Journal: Pediatr Blood Cancer Date: 2012-10-25 Impact factor: 3.167
Authors: Stephane Ducassou; Fanny Seyrig; Caroline Thomas; Anne Lambilliotte; Perrine Marec-Berard; Claire Berger; Genevieve Plat; Laurence Brugiere; Marie Ouache; Mohamed Barkaoui; Corinne Armari-Alla; Patrick Lutz; Guy Leverger; Xavier Rialland; Ludovic Mansuy; Helene Pacquement; Eric Jeziorski; Virginie Gandemer; François Chalard; Jean François Chateil; Abdellatif Tazi; Jean François Emile; Jean Donadieu Journal: Pediatr Blood Cancer Date: 2013-06-29 Impact factor: 3.167